Shopping Cart 0
Cart Subtotal
USD 0

Ferring International Center SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Ferring International Center SA (Ferring) researches, develops and markets pharmaceutical products. The company offers pharmaceutical products in the fields of reproductive health, gastroenterology, endocrinology, urology and orthopedics. Some of the marketed products include Rekovelle (follitropin delta), for controlled ovarian stimulation; Menopur (HP-hMG) for female and male infertility; Firmagon (degarelix) for prostate cancer; and Pentasa (mesalazine) for inflammatory bowel diseases. Its pipeline products encompass FE 999310 for infertility; FE 202767 for Lactation; Testavan for male hypogonadism; and Prefix for lumbar spine fusion, among others. Ferring conducts R&D on biotechnology derived medicines such as recombinant proteins and other biologics. It has production facilities in Europe, Asia and a manufacturing site in the US. Ferring is headquartered in Saint-Prex, Switzerland.

Ferring International Center SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ferring International Center SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Ferring International Center SA, Medical Devices Deals, 2012 to YTD 2018 10

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Ferring International Center SA, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Ferring International Center Acquire Ex-US Vitaros Assets and Rights from Apricus Biosciences 14

Ferring Pharma Acquires Global Rights to Milprosa from Teva Women's Health 16

Ferring Pharma to Acquire Novel Drug Delivery Technology from CTCBIO 17

Ferring Pharma Acquires Assets from BioSurface Engineering 18

Ferring Pharma Acquires Ddavp from Sanofi 19

Ferring International To Acquire Assets Of Al-Kindi Pharma For USD 6 Million 20

Partnerships 21

Ferring Pharma and Evotec Enter into Research Partnership 21

Ferring International and Celmatix Enter into Partnership 22

Enteris BioPharma Enters into Agreement with Ferring Pharma 23

Ferring Pharma and Chinese Academy of Sciences Enter into Agreement 24

LIDDS Enters into Research Agreement with Ferring Pharma 25

Ferring International and Alrise Biosystems Enter into Co-Development Agreement 26

Ferring Pharma Enters into Agreement with CD Investments 27

Ferring Pharma Enters into Partnership with ICF 28

Ferring Pharma Enters into Agreement with Intralytix 29

Ferring International Center Enters into Agreement with Ache Laboratorios Farmaceuticos 30

Ferring Pharma Enters into Co-Development Agreement with Karolinska Institutet 31

Apricus Biosciences Extends Distribution Agreement with Ferring Pharma 32

Ferring Pharma Enters into Co-Development Agreement with Roche 33

Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 34

Licensing Agreements 35

Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 35

Ferring International Enters into Licensing Agreement with Enteris BioPharma 36

Ferring International Enters into Licensing Agreement with IMAB 37

Levo Therapeutics Enters into Licensing Agreement with Ferring Pharma 38

Ferring Pharma Enters into Licensing Agreement with Seikagaku 39

Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 40

TxCell Enters into Licensing Agreement with Ferring International for Ovasave 41

Acquisition 43

Ferring Pharma Acquires Rebiotix 43

Ferring International Center SA-Key Competitors 44

Ferring International Center SA-Key Employees 45

Ferring International Center SA-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Recent Developments 50

Corporate Communications 50

Oct 02, 2017: Ferring appoints Klaus Dugi as Executive Vice President and Chief Medical Officer 50

May 23, 2017: Ferring commits USD 10 million to March of Dimes to expand research needed to end preterm birth 51

Apr 03, 2017: Ferring appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer 52

Product News 53

08/23/2017: Rebiotix to Present on RBX2660 at BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference 53

08/23/2017: Rebiotix to Present on RBX7455 at BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference 54

02/12/2018: Rebiotix Develops Microbiome Health Index to Identify Indicators for Microbiome Restoration 55

02/06/2017: Rebiotix to Present on RBX7455 at BIO CEO & Investor Conference 56

Product Approvals 57

Mar 15, 2018: Ferring announces positive outcome of European Decentralised Procedure for Testavan, a treatment for men with hypogonadism 57

Clinical Trials 58

Nov 29, 2017: Rebiotix Announces Expansion of Phase 1 Trial of the Companys Oral Capsule Microbiota Product, RBX7455, Following Successful Completion of Initial Study Arms 58

Nov 15, 2017: Rebiotix to Present on its Anti-Bacterial Agent RBX2660 at 29th Annual Piper Jaffray Healthcare Conference 59

Nov 15, 2017: Rebiotix to Present on its Anti-Bacterial Agent RBX7455 at 29th Annual Piper Jaffray Healthcare Conference 60

Oct 16, 2017: New Clinical Data and Microbiome Research from Rebiotix's Phase 2 Program for RBX2660 Highlighted at the World Congress of Gastroenterology at ACG2017 61

Oct 12, 2017: Rebiotix Announces New RBX2660 Data Including a Novel Microbiome Biomarker Analysis to be Presented at the World Congress of Gastroenterology at ACG2017 62

Oct 04, 2017: Presentations at ID Week 2017 Highlight Clinical Results and Microbiome Analysis of Patients Treated in Rebiotixs RBX2660 Phase 2 Studies 63

Aug 07, 2017: Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection 65

Jan 04, 2017: Rebiotix Treats First Patient in Phase 1 Study of RBX7455, an Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule for Recurrent Clostridium difficile Infection 66

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67


List Of Figure

List of Figures

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Ferring International Center SA, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Ferring International Center SA, Pharmaceuticals & Healthcare, Key Facts 2

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ferring International Center SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ferring International Center SA, Deals By Therapy Area, 2012 to YTD 2018 9

Ferring International Center SA, Medical Devices Deals, 2012 to YTD 2018 10

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Ferring International Center Acquire Ex-US Vitaros Assets and Rights from Apricus Biosciences 14

Ferring Pharma Acquires Global Rights to Milprosa from Teva Women's Health 16

Ferring Pharma to Acquire Novel Drug Delivery Technology from CTCBIO 17

Ferring Pharma Acquires Assets from BioSurface Engineering 18

Ferring Pharma Acquires Ddavp from Sanofi 19

Ferring International To Acquire Assets Of Al-Kindi Pharma For USD 6 Million 20

Ferring Pharma and Evotec Enter into Research Partnership 21

Ferring International and Celmatix Enter into Partnership 22

Enteris BioPharma Enters into Agreement with Ferring Pharma 23

Ferring Pharma and Chinese Academy of Sciences Enter into Agreement 24

LIDDS Enters into Research Agreement with Ferring Pharma 25

Ferring International and Alrise Biosystems Enter into Co-Development Agreement 26

Ferring Pharma Enters into Agreement with CD Investments 27

Ferring Pharma Enters into Partnership with ICF 28

Ferring Pharma Enters into Agreement with Intralytix 29

Ferring International Center Enters into Agreement with Ache Laboratorios Farmaceuticos 30

Ferring Pharma Enters into Co-Development Agreement with Karolinska Institutet 31

Apricus Biosciences Extends Distribution Agreement with Ferring Pharma 32

Ferring Pharma Enters into Co-Development Agreement with Roche 33

Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 34

Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 35

Ferring International Enters into Licensing Agreement with Enteris BioPharma 36

Ferring International Enters into Licensing Agreement with IMAB 37

Levo Therapeutics Enters into Licensing Agreement with Ferring Pharma 38

Ferring Pharma Enters into Licensing Agreement with Seikagaku 39

Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 40

TxCell Enters into Licensing Agreement with Ferring International for Ovasave 41

Ferring Pharma Acquires Rebiotix 43

Ferring International Center SA, Key Competitors 44

Ferring International Center SA, Key Employees 45

Ferring International Center SA, Other Locations 46

Ferring International Center SA, Subsidiaries 46

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Ferring International Center SA (Ferring) researches, develops and markets pharmaceutical products. The company offers pharmaceutical products in the fields of reproductive health, gastroenterology, endocrinology, urology and orthopedics. Some of the marketed products include Rekovelle (follitropin delta), for controlled ovarian stimulation; Menopur (HP-hMG) for female and male infertility; Firmagon (degarelix) for prostate cancer; and Pentasa (mesalazine) for inflammatory bowel diseases. Its pipeline products encompass FE 999310 for infertility; FE 202767 for Lactation; Testavan for male hypogonadism; and Prefix for lumbar spine fusion, among others. Ferring conducts R&D on biotechnology derived medicines such as recombinant proteins and other biologics. It has production facilities in Europe, Asia and a manufacturing site in the US. Ferring is headquartered in Saint-Prex, Switzerland.

Ferring International Center SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ferring International Center SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Ferring International Center SA, Medical Devices Deals, 2012 to YTD 2018 10

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Ferring International Center SA, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Ferring International Center Acquire Ex-US Vitaros Assets and Rights from Apricus Biosciences 14

Ferring Pharma Acquires Global Rights to Milprosa from Teva Women's Health 16

Ferring Pharma to Acquire Novel Drug Delivery Technology from CTCBIO 17

Ferring Pharma Acquires Assets from BioSurface Engineering 18

Ferring Pharma Acquires Ddavp from Sanofi 19

Ferring International To Acquire Assets Of Al-Kindi Pharma For USD 6 Million 20

Partnerships 21

Ferring Pharma and Evotec Enter into Research Partnership 21

Ferring International and Celmatix Enter into Partnership 22

Enteris BioPharma Enters into Agreement with Ferring Pharma 23

Ferring Pharma and Chinese Academy of Sciences Enter into Agreement 24

LIDDS Enters into Research Agreement with Ferring Pharma 25

Ferring International and Alrise Biosystems Enter into Co-Development Agreement 26

Ferring Pharma Enters into Agreement with CD Investments 27

Ferring Pharma Enters into Partnership with ICF 28

Ferring Pharma Enters into Agreement with Intralytix 29

Ferring International Center Enters into Agreement with Ache Laboratorios Farmaceuticos 30

Ferring Pharma Enters into Co-Development Agreement with Karolinska Institutet 31

Apricus Biosciences Extends Distribution Agreement with Ferring Pharma 32

Ferring Pharma Enters into Co-Development Agreement with Roche 33

Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 34

Licensing Agreements 35

Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 35

Ferring International Enters into Licensing Agreement with Enteris BioPharma 36

Ferring International Enters into Licensing Agreement with IMAB 37

Levo Therapeutics Enters into Licensing Agreement with Ferring Pharma 38

Ferring Pharma Enters into Licensing Agreement with Seikagaku 39

Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 40

TxCell Enters into Licensing Agreement with Ferring International for Ovasave 41

Acquisition 43

Ferring Pharma Acquires Rebiotix 43

Ferring International Center SA-Key Competitors 44

Ferring International Center SA-Key Employees 45

Ferring International Center SA-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Recent Developments 50

Corporate Communications 50

Oct 02, 2017: Ferring appoints Klaus Dugi as Executive Vice President and Chief Medical Officer 50

May 23, 2017: Ferring commits USD 10 million to March of Dimes to expand research needed to end preterm birth 51

Apr 03, 2017: Ferring appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer 52

Product News 53

08/23/2017: Rebiotix to Present on RBX2660 at BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference 53

08/23/2017: Rebiotix to Present on RBX7455 at BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference 54

02/12/2018: Rebiotix Develops Microbiome Health Index to Identify Indicators for Microbiome Restoration 55

02/06/2017: Rebiotix to Present on RBX7455 at BIO CEO & Investor Conference 56

Product Approvals 57

Mar 15, 2018: Ferring announces positive outcome of European Decentralised Procedure for Testavan, a treatment for men with hypogonadism 57

Clinical Trials 58

Nov 29, 2017: Rebiotix Announces Expansion of Phase 1 Trial of the Companys Oral Capsule Microbiota Product, RBX7455, Following Successful Completion of Initial Study Arms 58

Nov 15, 2017: Rebiotix to Present on its Anti-Bacterial Agent RBX2660 at 29th Annual Piper Jaffray Healthcare Conference 59

Nov 15, 2017: Rebiotix to Present on its Anti-Bacterial Agent RBX7455 at 29th Annual Piper Jaffray Healthcare Conference 60

Oct 16, 2017: New Clinical Data and Microbiome Research from Rebiotix's Phase 2 Program for RBX2660 Highlighted at the World Congress of Gastroenterology at ACG2017 61

Oct 12, 2017: Rebiotix Announces New RBX2660 Data Including a Novel Microbiome Biomarker Analysis to be Presented at the World Congress of Gastroenterology at ACG2017 62

Oct 04, 2017: Presentations at ID Week 2017 Highlight Clinical Results and Microbiome Analysis of Patients Treated in Rebiotixs RBX2660 Phase 2 Studies 63

Aug 07, 2017: Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection 65

Jan 04, 2017: Rebiotix Treats First Patient in Phase 1 Study of RBX7455, an Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule for Recurrent Clostridium difficile Infection 66

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67


List Of Figure

List of Figures

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Ferring International Center SA, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Ferring International Center SA, Pharmaceuticals & Healthcare, Key Facts 2

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ferring International Center SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ferring International Center SA, Deals By Therapy Area, 2012 to YTD 2018 9

Ferring International Center SA, Medical Devices Deals, 2012 to YTD 2018 10

Ferring International Center SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Ferring International Center Acquire Ex-US Vitaros Assets and Rights from Apricus Biosciences 14

Ferring Pharma Acquires Global Rights to Milprosa from Teva Women's Health 16

Ferring Pharma to Acquire Novel Drug Delivery Technology from CTCBIO 17

Ferring Pharma Acquires Assets from BioSurface Engineering 18

Ferring Pharma Acquires Ddavp from Sanofi 19

Ferring International To Acquire Assets Of Al-Kindi Pharma For USD 6 Million 20

Ferring Pharma and Evotec Enter into Research Partnership 21

Ferring International and Celmatix Enter into Partnership 22

Enteris BioPharma Enters into Agreement with Ferring Pharma 23

Ferring Pharma and Chinese Academy of Sciences Enter into Agreement 24

LIDDS Enters into Research Agreement with Ferring Pharma 25

Ferring International and Alrise Biosystems Enter into Co-Development Agreement 26

Ferring Pharma Enters into Agreement with CD Investments 27

Ferring Pharma Enters into Partnership with ICF 28

Ferring Pharma Enters into Agreement with Intralytix 29

Ferring International Center Enters into Agreement with Ache Laboratorios Farmaceuticos 30

Ferring Pharma Enters into Co-Development Agreement with Karolinska Institutet 31

Apricus Biosciences Extends Distribution Agreement with Ferring Pharma 32

Ferring Pharma Enters into Co-Development Agreement with Roche 33

Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 34

Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 35

Ferring International Enters into Licensing Agreement with Enteris BioPharma 36

Ferring International Enters into Licensing Agreement with IMAB 37

Levo Therapeutics Enters into Licensing Agreement with Ferring Pharma 38

Ferring Pharma Enters into Licensing Agreement with Seikagaku 39

Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 40

TxCell Enters into Licensing Agreement with Ferring International for Ovasave 41

Ferring Pharma Acquires Rebiotix 43

Ferring International Center SA, Key Competitors 44

Ferring International Center SA, Key Employees 45

Ferring International Center SA, Other Locations 46

Ferring International Center SA, Subsidiaries 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS